Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma

Joseph Schroers-Martin, Jurik A Mutter, Mohammad Shahrokh Esfahani, Florian Scherer, Joanne Soo, Stefan K. Alig, David M. Kurtz, Takeshi Sugio, Cédric Rossi, Benoit Tessoulin, Mari Olsen, Chih Long Liu, Maximilian Diehn, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 528.

https://doi.org/10.1182/blood-2023-187116

Published: 2023

Journal Articles

An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring

Takeshi Sugio, Navika Shukla, Michael S Khodadoust, Monica Nesselbush, Koji Kato, Stefan K. Alig, Jan Boegeholz, Joseph Schroers-Martin, Mohammad Shahrokh Esfahani, Jurik A. Mutter, Andrea Garofalo, Soyeong Jun, Mark P. Hamilton, Cédric Rossi, Mari Olsen, Chih Long Liu, Koichi Akashi, Maximilian Diehn, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2023-180492

Published: 2023

Journal Articles

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Blood (2023) 142 (Supplement 1): 177.

https://doi.org/10.1182/blood-2023-186810

Published: 2023

Journal Articles

First Line Therapy Evaluation Using Propensity Score Approach in Newly Diagnosed Advanced Classical Hodgkin Lymphoma Patients from Prospective Real-World Realysa Cohort and Phase 3 AHL2011 Trial

Cedric Rossi, Amira Marouf, Benedicte Deau Fischer, Fanny Cherblanc, Emeline Cugnod, Loic Chartier, Luc Matthieu Fornecker, Marc Andre, Rene-Olivier Casasnovas, Herve Ghesquieres

Blood (2023) 142 (Supplement 1): 3056.

https://doi.org/10.1182/blood-2023-178154

Published: 2023

Journal Articles

High IL1-RA Plasma Levels at Baseline Allow to Identify Hodgkin Lymphoma Patients with High Risk of Treatment Failure

Camille Fong Chih Kai, Bastien Lesne, Amandine Durand, Mathilde Stephan, François Godard, Daniela Lakomy, Camille Guibert, Laurent Martin, Romain Aucagne, Laurent Delva, Cédric Rossi, Rene-Olivier Casasnovas

Blood (2023) 142 (Supplement 1): 4389.

https://doi.org/10.1182/blood-2023-180802

Published: 2023

Journal Articles

Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification

Jurik A Mutter, Mohammad Shahrokh Esfahani, Joseph Schroers-Martin, Stefan K. Alig, Mark P. Hamilton, Brian J. Sworder, Benoit Tessoulin, Jan Boegeholz, Timothy Flerlage, Jamie E. Flerlage, Michael S. Binkley, Takeshi Sugio, Cédric Rossi, Mari Olsen, Chih Long Liu, Steven Le Gouill, David M. Kurtz, Maximilian Diehn, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 245.

https://doi.org/10.1182/blood-2023-186853

Published: 2023

Journal Articles

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Blood (2023) 142 (Supplement 1): 1717.

https://doi.org/10.1182/blood-2023-188545

Published: 2023

Journal Articles

Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults

Cédric Rossi, Jan Boegeholz, Stefan K. Alig, Andrea Garofalo, Mohammad Shahrokh Esfahani, Joseph Schroers-Martin, Mari Olsen, Xiaoman Kang, David M. Kurtz, Takeshi Sugio, Mark P. Hamilton, Marc Andre, Rene-Olivier Casasnovas, Luc Matthieu Fornecker, Maximilian Diehn, Herve Ghesquieres, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 4369.

https://doi.org/10.1182/blood-2023-178257

Published: 2023

Journal Articles

CD20low/CD68high a Promising Microenvironnement Profile Identifying Classical Hodgkin Lymphoma Patients with Poor Outcome a Lysa Study

Alexandra Traverse-Glehen, Laurent Martin, Camille Laurent, Peggy Dartigues, Barbara Burroni, Diane Damotte, Marie Parrens, Herve Ghesquieres, Marguerite Fournier, Salim Kanoun, Anne Ségolène Cottereau, Marc Andre, Cédric Rossi, René-Olivier Casasnovas

Blood (2023) 142 (Supplement 1): 3011.

https://doi.org/10.1182/blood-2023-174784

Published: 2023

Journal Articles

Synthetic Control Arm from Clinical Trials and Real-World Data from Lysa Group for Untreated Diffuse Large B Cell Lymphoma Patients Aged over 80 Years: A Bona Fide S trategy for Innovative Clinical Trials

Valentin Letailleur, Isabelle Chaillol, Fanny Cherblanc, Herve Ghesquieres, Frederic Peyrade, Fabrice Jardin, Stephanie Guidez, Fontanet Delices Bijou, Pierre Sesques, Cédric Rossi, Luc Matthieu Fornecker, Ludovic Fouillet, Sylvain Carras, Benoit Tessoulin

Blood (2023) 142 (Supplement 1): 72.

https://doi.org/10.1182/blood-2023-177708

Published: 2023

Journal Articles

Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling

Blood (2022) 140 (Supplement 1): 1295–1296.

https://doi.org/10.1182/blood-2022-164744

Published: 2022

Journal Articles

Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas

Blood (2022) 140 (Supplement 1): 1318–1319.

https://doi.org/10.1182/blood-2022-159230

Published: 2022

Journal Articles

Total Metabolic Tumor Volume and Tumor Dissemination Are Independent Prognostic Factors in Advanced Hodgkin Lymphoma

Salim Kanoun, Alina Berriolo-Riedinger, Anne Ségolène Cottereau, Veronique Edeline, Ilan Tal, Pauline Brice, Reda Bouabdallah, Herve Ghesquieres, Aspasia Stamatoullas-Bastard, Jehan Dupuis, Marc André, Thomas Gastinne, Julien Lazarovici, Samuel Griolet, Cedric Rossi, Michel Meignan, Rene-Olivier Casasnovas

Blood (2021) 138 (Supplement 1): 880.

https://doi.org/10.1182/blood-2021-147177

Published: 2021

Journal Articles

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Blood (2021) 137 (25): 3495–3506.

https://doi.org/10.1182/blood.2020007303

Published: 2021

Includes: Supplemental data

Journal Articles

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

Steven Le Gouill, Franck Morschhauser, David Chiron, Krimo Bouabdallah, Guillaume Cartron, Olivier Casasnovas, Caroline Bodet-Milin, Sylviane Ragot, Céline Bossard, Nathalie Nadal, Charles Herbaux, Benoit Tessoulin, Emmanuelle Tchernonog, Cédric Rossi, Rory McCulloch, Thomas Gastinne, Mary B. Callanan, Simon Rule

Blood (2021) 137 (7): 877–887.

https://doi.org/10.1182/blood.2020008727

Published: 2021

Includes: Supplemental data

Journal Articles

CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies

Blood (2020) 136 (21): 2428–2436.

https://doi.org/10.1182/blood.2020007092

Published: 2020

Includes: Supplemental data

Journal Articles

PVAG Regimen (Prednisone, Vinblastine, Doxorubicin, Gemcitabine) Used in Real-Life Setting in First Line Therapy for Elderly Classical Hodgkin Lymphoma Patients: A Retrospective Study of Lysa Centers

Guillaume Aussedat, Maryam Idlhaj, Amandine Durand, Xavier Roussel, Pauline Brice, MD, Gilles Salles, MDPhD, Benedicte Deau Fischer, Adrien Chauchet, MD, Cedric Rossi, MD PhD, Herve Ghesquieres, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-138706

Published: 2020

Journal Articles

R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-136600

Published: 2020

Journal Articles

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Cédric Rossi, MD PhD, Marc André, Clémentine Joubert, PhD, Catherine Fortpied, Pauline Brice, Bénédicte Deau-Fisher, MD, Herve Ghesquieres, MD PhD, Luc Mathieu Fornecker, MD PhD, Anne-Claire Gac, MD, Julien Lazarovici, Aspasia Stamatoullas, MD, John Raemakers, Massimo Federico, MD, Marie Maerevoet, MD, Sarah Bailly, MD, Salim Kanoun, MD, Michel Meignan, Anne Ségolène Cottereau, Rene-Olivier Casasnovas, MD

Blood (2019) 134 (Supplement_1): 128.

https://doi.org/10.1182/blood-2019-125976

Published: 2019

Journal Articles

Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

Steven Le Gouill, MD PhD, Franck Morschhauser, MD, Kamal Bouabdallah, MD, Guillaume Cartron, Olivier Casasnovas, MD, Thomas Gastinne, MD, Patrice Chevallier, MD, Cédric Rossi, MD PhD, Emmanuelle Tchernonog, MD, Rory McCulloch, FRCPath, MRCP, MBBS, Charles Herbaux, MD, David Chiron, PhD, Mary Callanan, PhD, Simon Rule

Blood (2019) 134 (Supplement_1): 1530.

https://doi.org/10.1182/blood-2019-125681

Published: 2019

NARROW

Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma

An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

First Line Therapy Evaluation Using Propensity Score Approach in Newly Diagnosed Advanced Classical Hodgkin Lymphoma Patients from Prospective Real-World Realysa Cohort and Phase 3 AHL2011 Trial

High IL1-RA Plasma Levels at Baseline Allow to Identify Hodgkin Lymphoma Patients with High Risk of Treatment Failure

Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults

CD20low/CD68high a Promising Microenvironnement Profile Identifying Classical Hodgkin Lymphoma Patients with Poor Outcome a Lysa Study

Synthetic Control Arm from Clinical Trials and Real-World Data from Lysa Group for Untreated Diffuse Large B Cell Lymphoma Patients Aged over 80 Years: A Bona Fide S trategy for Innovative Clinical Trials

Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling

Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas

Total Metabolic Tumor Volume and Tumor Dissemination Are Independent Prognostic Factors in Advanced Hodgkin Lymphoma

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies

PVAG Regimen (Prednisone, Vinblastine, Doxorubicin, Gemcitabine) Used in Real-Life Setting in First Line Therapy for Elderly Classical Hodgkin Lymphoma Patients: A Retrospective Study of Lysa Centers

R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only